Tests added line ablation with pulmonary vein isolation for persistent atrial fibrillation
Compares pulmonary vein isolation alone with added linear ablation in persistent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07106970, who can take part
Where in China
- Beijing Anzhen Hospital Affiliated to Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boston Scientific Corporation
- Trial code
- NCT07106970
- Record updated
- 26 October 2026
- Original description
This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibrillation (PerAF)Read full original descriptionShow less
Linear Ablation Added to Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone Using Pulsed Field Ablation for Persistent Atrial Fibrillation: a Multi-center Randomized Controlled Trial
This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibrillation (PerAF)
Inclusion: Study subjects are required to meet all the following inclusion criteria:; Subjects with an age range of 18 years or above and 80 years or below; Subjects have symptomatic, drug-resistant, persistent AF, defined as:; Symptomatic: these symptoms include but not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath; Drug-resistant: effectiveness failure of, intolerance to, or specific contraindication to at least one AAD; Persistent: continuous AF for > 90 days, i) with a minimum a physician's note confirming the diagnosis AND,within 180 days of Enrollment Date, either a 24-hour or longer continuous ECG recording confirming continuous AF OR Two ECGs showing continuous AF taken at least 90 days apart; Subjects undergoing a first-time ablation procedure for AF; Subjects who are willing and capable of providing ICF and participating in all testing associated with this study.
Exclusion: Left atrial anteroposterior diameter ≥ 6.0 cm by transthoracic echocardiography (TTE) within 3 months prior the procedure; LA thrombus detected by Transesophageal Echocardiography (TEE) or cardiac CT within one day before the procedure or Intracardiac Echocardiography (ICE) before atrial septal puncture during the procedure; AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible/non-cardiac causes; Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices, mechanical valve, interatrial baffle, closure device, patch, or patent foramen oval occlude, left atrial appendage closure at the time of ablation; Any of the following events within 90 days of the Consent Date:; Myocardial infarction, unstable angina or coronary intervention or any cardiac surgery; Pericarditis or symptomatic pericardial effusion; Gastrointestinal bleeding; Stroke, transient ischemic attack (TIA), or intracranial bleeding or any non-neurologic thromboembolic event; Subjects cannot be removed from Class I/III AAD for reasons other than atrial arrhythmia; Conditions that in the investigator's medical opinion would interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation; Heart failure with left ventricular ejection fraction (LVEF) < 30% by TTE within 3 months prior the procedure; Renal insufficiency if an estimated glomerular filtration rate (eGFR) is < 30 mL/min/1.73 m2, or with any history of renal dialysis or renal transplant; Contraindication to, or unwillingness to use systemic anticoagulation; Women of childbearing potential who are pregnant or lactating; Predicted life expectancy less than 12 months.